Prana today provided a business update on its development portfolio of potential neurodegenerative treatments.
Prana Biotechnology will host a webcast at its Annual General Meeting on Thursday 17th November 2016 at 9.30am AEDT.
Prana today announced that is has received further advice from the US Food and Drug Administration (FDA) on the steps necessary to remove the Partial Clinical Hold (PCH) on PBT2, including the requirement to undertake further non-clinical studies.
Prana has today announced that it has received a A$4.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.
Prana today announced it has filed its Annual Report on Form 20-F
Professor Rudolph Tanzi presents results from testing PBT2 in the “Alzheimer’s in a Dish Model” at the Alzheimer’s Association International Conference in Toronto, Canada.
Abstract from Movement Disorders Conference 2016